BioImpact Capital LLC, 10% Owner at Cullinan Oncology, Inc. (CGEM), sold 46,506 shares at $29.35 ($1.4M) on 2021-09-09, disclosed to the SEC on 2021-09-13.
Scheduled sale ($1.4M) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.35 | 13,727 | $403K | 29.6% |
| 2 | $29.35 | 13,727 | $403K | 29.6% |
| 3 | $29.04 | 5,931 | $172K | 12.7% |
| 4 | $29.04 | 5,931 | $172K | 12.7% |
| 5 | $29.10 | 3,595 | $105K | 7.7% |
| 6 | $29.10 | 3,595 |
| $105K |
| 7.7% |
| Total | $29.23 avg | 46,506 | $1.4M | 100% |
| Filing → |
| CGEM | SELL | 2021-09-20 | $182K | — | Filing → |
| CGEM | SELL | 2021-09-16 | $602K | — | Filing → |
| ITOS | SELL | 2021-09-13 | $5.5M | — | Filing → |